FundedIQ
Biotechnology

Noxxon Pharma: Funding, Investors & Team (Sep 2026)

NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

www.noxxon.com LinkedIn Berlin, Germany 51-100 employees
Total raised
$19.3M
Rounds
1
Latest
Post-IPO Debt
Jan 2022

Noxxon Pharma has raised $19.3M across 1 funding round on record, the most recent a Post-IPO Debt of $19.3M announced in Jan 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Noxxon Pharma Company Profile and Key Stats

Total funding raised
$19.3M
across 1 round on record
Funding rounds on record
1
Latest funding round
Post-IPO Debt
$19.3M in Jan 2022
Employees
51-100
reported band
Headquarters
Berlin, Germany

Latest funding round on record: Jan 2022.

Noxxon Pharma Funding Rounds

Date
Round
Amount
Post-IPO Debt
$19.3M

Noxxon Pharma Founders and Leadership Team

Name
Role
Contact
Aram Mangasarian
CEO
Locked

Contact details for the Noxxon Pharma team: 1 of 1 has an email address on file.

Start 14-day free trial →

Noxxon Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
1,817
$6.5M

Noxxon Pharma's latest round of $19.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Noxxon Pharma in Biotechnology and Berlin

Companies Similar to Noxxon Pharma

Noxxon Pharma Funding FAQs

What does Noxxon Pharma do?

NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

How much funding has Noxxon Pharma raised?

Noxxon Pharma has raised $19.3M across 1 round on record. The most recent is a Post-IPO Debt of $19.3M announced in Jan 2022.

When did Noxxon Pharma last raise funding?

Noxxon Pharma's most recent funding round on record is a Post-IPO Debt of $19.3M, announced in Jan 2022.

Who is the CEO of Noxxon Pharma?

Aram Mangasarian is listed as CEO at Noxxon Pharma.

Where is Noxxon Pharma headquartered?

Noxxon Pharma is based in Berlin, Germany.

How many employees does Noxxon Pharma have?

Noxxon Pharma is in the 51-100 employee band.

How does Noxxon Pharma's funding compare to other Biotechnology startups?

Noxxon Pharma's latest round of $19.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Noxxon Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Noxxon Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.